Understanding Syphilis Testing
Syphilis is a bacterial sexually transmitted infection caused by the spirochete bacterium Treponema pallidum. If left untreated, syphilis progresses through distinct stages—primary, secondary, latent, and tertiary—each with characteristic clinical manifestations and increasing severity. Early detection through blood testing enables prompt antibiotic treatment, preventing progression to advanced stages that can cause irreversible damage to the heart, brain, nerves, and other organs. In the UK, syphilis rates have increased significantly in recent years, making routine screening increasingly important for sexually active individuals.
Syphilis testing relies on serological methods that detect antibodies produced in response to Treponema pallidum infection. Two categories of tests are used: non-treponemal tests (such as RPR - Rapid Plasma Reagin) and treponemal tests (such as TPPA - Treponema Pallidum Particle Agglutination). Non-treponemal tests detect antibodies against lipoid material released from damaged cells during infection and are useful for screening and monitoring treatment response. Treponemal tests detect antibodies specific to T. pallidum proteins, confirming true infection and distinguishing false positives from genuine cases.
Clinical Stages of Syphilis
Primary syphilis typically manifests 10-90 days after infection (average 21 days) as a painless ulcer called a chancre at the site of bacterial entry, most commonly on the genitals, anus, or mouth. The chancre is highly infectious but often goes unnoticed, particularly when located internally. It heals spontaneously within 3-6 weeks without treatment, but the infection persists and progresses. During this stage, serological tests may be negative initially, becoming positive as the immune response develops.
Secondary syphilis develops 4-10 weeks after the chancre appears, characterised by systemic dissemination of T. pallidum throughout the body. Classic manifestations include a non-itchy rash affecting the palms and soles, mucous patches in the mouth or genitals, generalised lymphadenopathy (swollen lymph nodes), fever, fatigue, and hair loss. Secondary syphilis is highly infectious. Without treatment, symptoms resolve spontaneously but infection enters the latent stage. Serological tests are strongly positive during secondary syphilis, enabling straightforward diagnosis.
Latent and Tertiary Syphilis
Latent syphilis represents asymptomatic infection detectable only through positive serological testing. Early latent syphilis (infection within the previous 12 months) carries risk of relapse to secondary syphilis and remains infectious. Late latent syphilis (infection exceeding 12 months) is generally non-infectious except during pregnancy, when vertical transmission to the foetus can occur. Without treatment, approximately one-third of individuals with latent syphilis progress to tertiary syphilis, which can develop decades after initial infection.
Tertiary syphilis causes severe, potentially fatal complications affecting the cardiovascular system (aortic aneurysm, aortic regurgitation), central nervous system (neurosyphilis causing dementia, ataxia, paralysis), and other organs. Gummas (granulomatous lesions) can develop in skin, bone, and internal organs. Tertiary syphilis represents irreversible tissue damage that cannot be reversed by antibiotic treatment, though treatment prevents further progression. Modern screening and treatment have made tertiary syphilis rare in developed countries, but cases still occur in individuals with undiagnosed or untreated infection.
Syphilis Serological Testing Methods
RPR (Rapid Plasma Reagin) testing detects non-specific antibodies (reagin) produced against cardiolipin, a lipid released from cells damaged during syphilis infection. RPR is quantitative, reported as a titre (dilution at which the test remains positive), making it valuable for monitoring treatment response—successful treatment causes RPR titres to decline and eventually become negative. However, RPR can produce false positives in pregnancy, autoimmune diseases, acute infections, and following vaccination, necessitating confirmatory treponemal testing.
TPPA (Treponema Pallidum Particle Agglutination) testing detects antibodies specifically directed against T. pallidum antigens. TPPA confirms true syphilis infection, distinguishing genuine cases from RPR false positives. Unlike RPR, TPPA typically remains positive for life even after successful treatment, making it unsuitable for monitoring treatment response but excellent for confirming infection. Modern syphilis screening often employs reverse sequence testing, using treponemal tests (like TPPA) for initial screening followed by non-treponemal tests (RPR) for positive cases to enable staging and treatment monitoring.
Treatment and Prevention
Syphilis treatment relies on benzathine penicillin G, administered as intramuscular injection. Early syphilis (primary, secondary, early latent) typically requires a single injection, whilst late latent or tertiary syphilis requires three weekly injections. Penicillin-allergic patients may receive alternative antibiotics such as doxycycline, though penicillin remains most effective. Treatment rapidly eliminates T. pallidum, rendering patients non-infectious within 24 hours, though serological tests remain positive for extended periods.
Following treatment, patients require serological monitoring at 3, 6, and 12 months to confirm treatment success, demonstrated by declining RPR titres. Sexual partners require testing and treatment. Condom use significantly reduces syphilis transmission risk but does not provide complete protection, as syphilis can be transmitted through contact with lesions not covered by condoms. Regular screening is essential for sexually active individuals, particularly those with multiple partners, MSM (men who have sex with men), or those with a partner diagnosed with syphilis.